BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 24635868)

  • 1. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
    Hoffe S; Rao N; Shridhar R
    Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of radiation therapy in patients with resectable pancreatic cancer.
    Palta M; Willett C; Czito B
    Oncology (Williston Park); 2011 Jul; 25(8):715-21, 727. PubMed ID: 21874833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pancreatic carcinoma. Optimizing therapy by adjuvant and neoadjuvant therapy?].
    Maurer CA; Zgraggen K; Büchler MW
    Zentralbl Chir; 1999; 124(5):401-7. PubMed ID: 10420525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer.
    Sen N; Falk S; Abrams RA
    Clin Oncol (R Coll Radiol); 2014 Sep; 26(9):551-9. PubMed ID: 25024090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
    D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
    Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
    Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
    Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings.
    Franke AJ; Rosati LM; Pawlik TM; Kumar R; Herman JM
    Semin Oncol; 2015 Feb; 42(1):144-62. PubMed ID: 25726059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies.
    Kleeff J; Michalski CW; Friess H; Büchler MW
    Eur J Surg Oncol; 2007 Sep; 33(7):817-23. PubMed ID: 17331695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the management of borderline resectable pancreatic cancers.
    Goodman MD; McPartland S; Huber K; Saif MW
    JOP; 2013 Jul; 14(4):334-6. PubMed ID: 23846921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
    Goff SL; Chabot JA
    Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
    Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer.
    Chandhok NS; Saif MW
    JOP; 2014 Mar; 15(2):91-4. PubMed ID: 24618425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma in 2006].
    Deberne M; Huguet F; Le Scodan R; Hammel P; Andre T
    Bull Cancer; 2007 Jan; 94(1):72-80. PubMed ID: 17237007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?
    Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S
    Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant therapy in pancreatic cancer].
    Ji JF; Li ZY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):644-7. PubMed ID: 16274051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of neoadjuvant therapy in pancreatic cancer: a review.
    Russo S; Ammori J; Eads J; Dorth J
    Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.